<DOC>
	<DOCNO>NCT01966731</DOCNO>
	<brief_summary>REACH prospective , phase I/II open-label dose escalation trial hydroxyurea child confirm SCA 12 month 10 year age . The short-term goal obtain critical pilot data regard feasibility , safety , benefit hydroxyurea child SCA multiple distinct research setting Africa . Based information , longer-term goal make hydroxyurea widely available child SCA Africa , particularly identify SCA expand newborn screening program .</brief_summary>
	<brief_title>Realizing Effectiveness Across Continents With Hydroxyurea ( REACH )</brief_title>
	<detailed_description>STUDY OBJECTIVES 1 . To assess feasibility conduct prospective research study use hydroxyurea therapy SCA sub-Saharan Africa ( include adherence monthly clinic visit laboratory assessment , medication compliance ) 2 . To monitor safety hydroxyurea therapy , specifically document hematological toxicity ( cytopenia ) serious infection ( bacterial malarial ) 3 . To evaluate benefit hydroxyurea therapy , use laboratory ( e.g. , fetal hemoglobin , hemoglobin , white blood cell count ) clinical parameter ( e.g. , pain , hospitalization , growth ) 4 . To investigate effect hydroxyurea dose escalation laboratory clinical parameter</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Inclusion Criteria 1 . Pediatric patient document sickle cell anemia ( typically HbSS support hemoglobin electrophoresis , complete blood count , peripheral blood smear ) 2 . Age range 1.009.99 year , inclusive , time enrollment 3 . Weight least 10.0 kg time enrollment 4 . Parent guardian willing able provide write informed consent , child 's verbal assent per local IRB/Ethics Board requirement 5 . Willingness comply studyrelated treatment , evaluation , followup Exclusion Criteria 1 . Known medical condition make participation illadvised , ( e.g. , acute chronic infectious disease , HIV , malignancy ) 2 . Acute chronic severe malnutrition determine impaired growth parameter define WHO ( weight length/height weightforlength/height &gt; 3 zscores median WHO growth standard , define Appendix I ) 3 . Preexisting severe hematological toxicity ( temporary exclusion ) 1 . Anemia : Hb &lt; 4.0 gm/dL 2 . Anemia : Hb &lt; 6.0 gm/dL ARC &lt; 100 x 109/L 3 . Reticulocytopenia : ARC &lt; 80 x 109/L Hb &lt; 7.0 gm/dL 4 . Thrombocytopenia : Platelets &lt; 80 x 109/L 5 . Neutropenia : ANC &lt; 1.0 x 109/L 4 . Blood transfusion within 60 day enrollment ( temporary exclusion ) 5 . Hydroxyurea use within 6 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Africa</keyword>
</DOC>